Brief: Nxera Pharma Reports Positive Results From Phase 3 Trial Of Daridorexant In South Korea
19/01/2026 14:31
Jan 19 (Reuters) - Nxera Pharma Co Ltd 4565.T: NXERA PHARMA REPORTS POSITIVE RESULTS FROM PHASE 3 TRIAL OF DARIDOREXANT IN SOUTH KOREA NXERA PHARMA CO LTD - DARIDOREXANT PHASE 3 TRIAL IN SOUTH KOREA MEETS EFFICACY ENDPOINTS NXERA PHARMA CO LTD - TO SUBMIT DARIDOREXANT MARKETING APPLICATION IN SOUTH KOREA Q1 2026 Source text: ID:nGNXblW9GQ Further company coverage: 4565.T ((Reuters.Briefs@thomsonreuters.com))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up